All4Cure 01 - CARE: A Crowd Sourcing Platform for Patients with Cancer.
Indication: Triple-negative breast cancer
Celcuity- CELC-G-301- (VIKTORIA-1)- A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (EXIGENT)
Indication: HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Breast- Olema Pharmaceuticals- OP-1250-003- A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination with the CDK4/6 Inhibitor Ribociclib, with the PI3K Inhibitor Alpelisib, or with the mTOR inhibitor Everolimus in Adult Subjects with Advanced and/or Metastatic ER Positive, HER2 Negative Breast cancer. (Exigent)
Indication: ER positive ( speak to coordinator)
Breast- Gilead-GS-US-595-6184- ASCENT-05- A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (Exigent)
Indication: Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Breast - Stemline STML-ELA-0222 (ELEVATE)-A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer
Indication: Metastatic Breast Cancer
Breast- Stemline Therapeutics- STML-ELA-0322-An open-label multicenter phase 2 study (ELCIN) Elacestrant in women and men with CDK4/6 Inhibitor-Naïve estrogen receptor positive, HER2 negative metastatic breast cancer
Indication: CDK4/6 Inhibitor-Naïve estrogen receptor positive, HER2 negative metastatic breast cancer
Breast- AstraZeneca-(CAPitello-292)-Capivasertib (AZD5363)- D361DC00001-A Phase lb/III Open-label, Randomized Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer
Indication: Advanced/Metastatic HR+/HER2-Breast Cancer
BREAST- S2206, Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Indication: ER positive, HER2 negative early-stage breast cancer
Breast- AstraZeneca-D926QC00001-TROPION-Breast04- A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab followed
by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer.
Indication: Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Breast-AstraZeneca Tropion Breast 5-D7630C00001-A Phase III, Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Indication: PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Breast- Genentech- CO44657-A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT, BOTH COMBINED WITH A CDK4/6 INHIBITOR, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY- pionERA
Indication: (ER+), HER2-negative Advanced Breast cancer/ resistant to adjuvant endocrine therapy
Breast- Stemline Therapeutics, Inc.-STML-ELA-0422- Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Indication: Early Breast Cancer with High Risk of Recurrence
BREAST- A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
Indication: BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast- Merck 012-06- A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery.
Indication: Triple-Negative Breast Cancer (TNBC)
Gastric- Henlius -HLX22-GC-301- A Randomized, Double-blinded, Multicenter, Phase3 Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
Indication: Gastroesophageal Junction and Gastric Cancer
All4Cure 01 - CARE: A Crowd Sourcing Platform for Patients with Cancer.
Indication: Triple-negative breast cancer
Sample Collection- BGER001 -BEGIN (BostonGene and Exigent Genomic INsight)-A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting
Indication: Advanced Cancer
Head/Neck- AstraZeneca D798EC00001- A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)
Indication: Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
Solid Tumor- Amgen- 20230223-subprotocol B- A Phase 1b Substudy evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG 193 in combination with mFolfirinox or Gemcitabine and Nab-paclitaxel in subjects with locally advanced or metastatic pancreatic ductal adenocarcinoma(PDAC) with homozygous MTAP-deletion (subprotocol B)
Indication: locally advanced or metastatic pancreatic ductal adenocarcinoma(PDAC) with homozygous MTAP-deletion
Breast- Olema Pharmaceuticals- OP-1250-003- A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination with the CDK4/6 Inhibitor Ribociclib, with the PI3K Inhibitor Alpelisib, or with the mTOR inhibitor Everolimus in Adult Subjects with Advanced and/or Metastatic ER Positive, HER2 Negative Breast cancer. (Exigent)
Indication: ER positive ( speak to coordinator)
Breast - Stemline STML-ELA-0222 (ELEVATE)-A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer
Indication: Metastatic Breast Cancer
NEO212-01- AN OPEN-LABEL, PHASE 1/2 DOSE FINDING, SAFETY AND EFFICACY STUDY OF NEO212 IN PATIENTS WITH ASTROCYTOMA IDH MUTANT, GLIOBLASTOMA IDH WILDTYPE OR UNCONTROLLED METASTASIS TO THE BRAIN IN PATIENTS WITH SELECT SOLID TUMORS
Indication: ASTROCYTOMA IDH MUTANT, GLIOBLASTOMA IDH WILDTYPE OR UNCONTROLLED METASTASIS TO THE BRAIN
Malignant Heme- AbbVie M23-324: A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies.
Indication: B-Cell Malignancies with MALT1 Inhibitor
Abbvie- M23-385- A phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budgalimab ( ABBV-181), Carboplatin, or cisplatin in adult subjects with advanced solid tumors.
Indication: Advanced solid tumors / SCLC, High- grade CNS tumors
Solid Tumor- Amgen-20230167-A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP deletion (Master Protocol)
Indication: Advanced Thoracic Tumors With Homozygous MTAP-deletion, NSCLC .Subprotocols A,B,C
Solid Tumor- Amgen- 20230223-subprotocol B- A Phase 1b Substudy evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG 193 in combination with mFolfirinox or Gemcitabine and Nab-paclitaxel in subjects with locally advanced or metastatic pancreatic ductal adenocarcinoma(PDAC) with homozygous MTAP-deletion (subprotocol B)
Indication: locally advanced or metastatic pancreatic ductal adenocarcinoma(PDAC) with homozygous MTAP-deletion
Solid Tumor- Hutchmed- 2022-523-GLOB1- A multicenter, Phase 1b study to evaluate the safety and tolerability, pharmacokinetics and preliminary efficacy of HMPL-523 a Syk Inhibitor in adult subjects with immune thrombocytopenia
Indication: immune thrombocytopenia
Malignant Heme- AbbVie M24-108- A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma
Indication: Relapsed or Refractory Multiple Myeloma
Phase 1/Prostate- Astellas Pharma- PRL-02-1001-Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02(PRL-02 Depot (abiraterone decanoate)) Depot in Patients with Advanced Prostate Cancer.
Indication: Prostate Cancer
Solid Tumor Phase 1-MediLink Therapeutics- YL201-INT-101-01- A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 in Patients With Advanced
Solid Tumors
Indication: Advanced solid tumors
Lung- Daiichi U31402-A-U102-A Multicenter, Open-Label Phase 1 Study of HER3-DXd in Subjects with Metastatic or Unresectable Non-Small Cell Lung Cancer.
Indication: Metastatic or Unresectable Non-Small Cell Lung Cancer
Phase 1- DualityBIO INC.- DB-1305-O-1001- A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects with Advanced/Metastatic Solid Tumors.
Indication: Advanced/ Metastatic Solid Tumors
Prostate- AstraZeneca-D9723C00001- EvoPAR-Prostate01- A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer
Indication: HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer
Phase 1/Prostate- Astellas Pharma- PRL-02-1001-Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02(PRL-02 Depot (abiraterone decanoate)) Depot in Patients with Advanced Prostate Cancer.
Indication: Prostate Cancer
Compassionate Use/Expanded Access/Emergency Use CARE: For a cancer patient who has exhausted all lines of traditional treatment and conventional trials. These are “trials” in which the FDA and pharmaceutical companies work together to bring a specific agent for treatment to a patient which otherwise would not be available.
Indication: Any cancer where lines of traditional/conventional treatment has been exhausted
Glioma - Neonc technologies- Neo100-01- Phase 2A- AN OPEN-LABEL, PHASE 1/2A DOSE ESCALATION STUDY OF SAFETY AND EFFICACY OF NEO100 IN RECURRENT OR PROGRESSIVE GRADE III OR IV GLIOMAS WITH IDH1 MUTATION - CARE
Indication: Grade IV gliomas
Glioblastoma- NeOnc technologies- NEO212-01- AN OPEN-LABEL, PHASE 1/2 DOSE FINDING, SAFETY AND EFFICACY STUDY OF ORAL NEO212 IN PATIENTS WITH ASTROCYTOMA IDH- MUTANT, GLIOBLASTOMA IDH-WILDTYPE OR UNCONTROLLED METASTASIS TO THE BRAIN IN PATIENTS WITH SELECT SOLID TUMORS
Indication: Astrocytoma IDH-mutant, Glioblastoma IDH- wildtype, or advanced solid tumors with uncontrolled metastases to the brain
Lung- Shanghai Henlius Biotech, Inc.Protocol HLX10-005-SCLC301-E-(ASTRIDE) A Randomized, Open-label Study of HLX10 plus Chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Indication: Previously Untreated US Patients with Extensive Stage Small Cell Lung
Lung- Anheart AB-106-G208- A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
Indication: ROS1 Positive NSCLC or other Solid Tumors
Lung-Regeneron Pharmaceuticals Inc.-R2810-ONC-2045- A Phase 1/2 study of Cemiplimab (anti-PD-1 Antibody) in combination with BNT116( FixVac Lung) Versus Cemiplimab monotherapy in first-line treatment of patients with advanced Non-small cell Lung cancer with tumors expressing PD-L1 equal or greater than 50 %
Indication: Advanced non small cell lung cancer
LUNG- AstraZeneca-D798AC00001-eVOLVE-Lung02- A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Indication: Metastatic Non-Small Cell Lung Cancer
Solid Tumor- Amgen-20230167-A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP deletion (Master Protocol)
Indication: Advanced Thoracic Tumors With Homozygous MTAP-deletion, NSCLC .Subprotocols A,B,C
LUNG- AstraZeneca Tropion-Lung10- D7632C00001- Phase 3 open-label study of first line Dato-Dxd in combination with Rilvegostomig for Advanced Non-Squamous NSCLC with high PD-L1 expression (TC>50%) and without actionable genomic alterations.
Indication: Advanced Non-Squamous NSCLC with high PD-L1 expression
Lung-Abbvie M25-274- A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
Indication: Non-Squamous Non-Small Cell Lung Cancer
Lung- OSE Immunotherapeutics-OSE2101C302-A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI)- ARTEMIA study
Indication: metastatic Non-Small Cell Lung Cancer (NSCLC)
Lung- AstraZeneca D702BC00001- A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
Indication: Metastatic Squamous Non-small Cell Lung Cancer
Lung- AstraZeneca D702FC00001- A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
Indication: Metastatic Non-squamous Non-small Cell Lung Cancer
RRMM- BristolMeyersSquibb- CA057-008-(QCCA)-A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM).
Indication: Relapsed or Refractory Multiple Myeloma (RRMM).
Malignant Heme- AbbVie M23-324: A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies.
Indication: B-Cell Malignancies with MALT1 Inhibitor
Malignant Heme- AZ D8227C00002 (ACRUE) A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma
Indication: Treatment-naïve elderly and/or frail patients with DLBCL
Malignant Heme- BeiGene- BGB-3111-308- Mahogany- A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma
Indication: Relapsed/Refractory Follicular Lymphoma
Malignant Heme- Kartos Therapeutics- KRT-232-115- A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Indication: JAK Inhibitor-Naïve Patients with Myelofibrosis
Malignant Heme- AbbVie M24-108- A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma
Indication: Relapsed or Refractory Multiple Myeloma
Malignant Heme- Janssen-64007957MMY3006- MajesTEC-9 - A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide ****Part 1 is closed. Part 2 is open for Teclistamab monotherapy****
Indication: Relapsed or Refractory Multiple Myeloma
Malignant Heme- Abbvie M24-287-A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects with CLL
Indication: Previously untreated subjects with CLL
Malignant Heme- Abbvie M22-003--A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2).
Indication: Folicular lymphoma
Compassionate Use/Expanded Access/Emergency Use CARE: For a cancer patient who has exhausted all lines of traditional treatment and conventional trials. These are “trials” in which the FDA and pharmaceutical companies work together to bring a specific agent for treatment to a patient which otherwise would not be available.
Indication: Any cancer where lines of traditional/conventional treatment has been exhausted
Lung- Anheart AB-106-G208- A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
Indication: ROS1 Positive NSCLC or other Solid Tumors
UW/CARE - Halpern A14788 CARE: Observational study protocol “Venetoclax in Combination with Azacitidine or Decitabine for Patients with Newly-diagnosed Acute Myeloid Leukemia (AML) and High-grade Myelodysplastic Syndrome (MDS) Who are Medically Unfit for Intensive Induction
Indication: Newly-diagnosed Acute Myeloid Leukemia (AML) and High-grade Myelodysplastic Syndrome (MDS)
Solid Tumor- Hutchmed- 2022-523-GLOB1- A multicenter, Phase 1b study to evaluate the safety and tolerability, pharmacokinetics and preliminary efficacy of HMPL-523 a Syk Inhibitor in adult subjects with immune thrombocytopenia
Indication: immune thrombocytopenia
Sample Collection- BillionToOne- NS-002- BillionToOne Northstar Response Clinical Validation Study
Indication: Patients about to start a new line of systemic therapy
Sample Collection- BGER001 -BEGIN (BostonGene and Exigent Genomic INsight)-A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting
Indication: Advanced Cancer
Specimen collection- Ovation-Collection of Biological Specimens and Associated Health Information for Secondary Research in Future Studies.
Indication: active cancer diagnosis
Observational-Personalis- 01-PS-001-Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)
Indication: early-stage Triple Negative Breast Cancer.
Observational- JnJ-Protocol 54767414NAP4001-A Non-interventional, Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)HALO
Indication: Severe and Fatal Infusion-related Reactions
Compassionate Use/Expanded Access/Emergency Use CARE: For a cancer patient who has exhausted all lines of traditional treatment and conventional trials. These are “trials” in which the FDA and pharmaceutical companies work together to bring a specific agent for treatment to a patient which otherwise would not be available.
Indication: Any cancer where lines of traditional/conventional treatment has been exhausted
Abbvie- M23-385- A phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budgalimab ( ABBV-181), Carboplatin, or cisplatin in adult subjects with advanced solid tumors.
Indication: Advanced solid tumors / SCLC, High- grade CNS tumors
Solid Tumor- Amgen-20230167-A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP deletion (Master Protocol)
Indication: Advanced Thoracic Tumors With Homozygous MTAP-deletion, NSCLC .Subprotocols A,B,C
Solid Tumor Phase 1-MediLink Therapeutics- YL201-INT-101-01- A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 in Patients With Advanced
Solid Tumors
Indication: Advanced solid tumors
Lung- OSE Immunotherapeutics-OSE2101C302-A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI)- ARTEMIA study
Indication: metastatic Non-Small Cell Lung Cancer (NSCLC)